Literature DB >> 24560928

Survivin beyond physiology: orchestration of multistep carcinogenesis and therapeutic potentials.

Kalliopi Ch Athanasoula1, Helen Gogas2, Katerina Polonifi2, Aristeidis G Vaiopoulos2, Aristidis Polyzos2, Marina Mantzourani2.   

Abstract

Survivin, a member of the inhibitor of apoptosis protein family, has been associated with protection from cell apoptosis and regulation of mitosis. Survivin exhibits low to undetectable expression in most finally differentiated adult tissues but is abundantly over-expressed in almost all cancers. The aberrant high expression of survivin in cancers is associated with advanced disease, increased rate of tumor recurrence, abbreviated overall survival and resistance to chemo- and radio- therapy. Survivin touches nearly every aspect of cancer and is involved in the initiation, maintenance and development of tumor. Therefore, its significance in cancer dictates the pursuit for anti-survivin cancer therapies.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Anti-apoptotic protein; Cancer; IAP family; Survivin; Targeted therapy

Mesh:

Substances:

Year:  2014        PMID: 24560928     DOI: 10.1016/j.canlet.2014.02.014

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  27 in total

Review 1.  Diagnostic value of survivin for malignant pleural effusion: a clinical study and meta-analysis.

Authors:  Panwen Tian; Yongchun Shen; Chun Wan; Ting Yang; Jing An; Qun Yi; Lei Chen; Tao Wang; Ye Wang; Fuqiang Wen
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

2.  Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma.

Authors:  Angela C Hirbe; Sonika Dahiya; Christopher A Miller; Tiandao Li; Robert S Fulton; Xiaochun Zhang; Sandra McDonald; Katherine DeSchryver; Eric J Duncavage; Jessica Walrath; Karlyne M Reilly; Haley J Abel; Melike Pekmezci; Arie Perry; Timothy J Ley; David H Gutmann
Journal:  Clin Cancer Res       Date:  2015-04-29       Impact factor: 12.531

3.  AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell.

Authors:  Gang Han; Hangjun Gong; Yidong Wang; Shaowen Guo; Kun Liu
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

4.  Oxymatrine inhibits proliferation of human bladder cancer T24 cells by inducing apoptosis and cell cycle arrest.

Authors:  Shun Li; Yi Zhang; Qingyong Liu; Qingli Zhao; Liuyu Xu; Shengliang Huang; Shiming Huang; Xuebin Wei
Journal:  Oncol Lett       Date:  2017-04-07       Impact factor: 2.967

5.  Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status.

Authors:  Christopher T Cummings; Weihe Zhang; Kurtis D Davies; Gregory D Kirkpatrick; Dehui Zhang; Deborah DeRyckere; Xiaodong Wang; Stephen V Frye; H Shelton Earp; Douglas K Graham
Journal:  Mol Cancer Ther       Date:  2015-07-10       Impact factor: 6.261

6.  Recent Advances on Small-Molecule Survivin Inhibitors

Authors:  Min Xiao; Wei Li
Journal:  Curr Med Chem       Date:  2015-01-13       Impact factor: 4.530

7.  Effects of survivin on FVADT chemotherapy for refractory multiple myeloma.

Authors:  Hua Yang; Xingjun Du; Yuren Xi
Journal:  Exp Ther Med       Date:  2016-05-26       Impact factor: 2.447

Review 8.  Survivin splice variants and their diagnostic significance.

Authors:  Nand K Sah; Chandrabhan Seniya
Journal:  Tumour Biol       Date:  2015-08-06

9.  A chromosomal passenger complex protein signature model predicts poor prognosis for non-small-cell lung cancer.

Authors:  Rong Xia; Sunxiao Chen; Yan Chen; Weiwei Zhang; Rongrong Zhu; Anmei Deng
Journal:  Onco Targets Ther       Date:  2015-04-07       Impact factor: 4.147

10.  Overexpression of BIRC6 Is a Predictor of Prognosis for Colorectal Cancer.

Authors:  Tingting Hu; Shuqiang Weng; Wenqing Tang; Ruyi Xue; She Chen; Guoxiang Cai; Yu Cai; Xizhong Shen; Si Zhang; Ling Dong
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.